Transarterial embolization, a catheter-based technique that deliberately occludes selected blood vessels, has quietly grown from an emergency tool for pelvic trauma into one of the most versatile procedures in interventional radiology. A new narrative review published in CVIR Endovascular maps the full breadth of its musculoskeletal applications, sorting them by how mature the evidence actually is. The verdict is strikingly nuanced: some uses are firmly established, others sit in an intermediate zone, and the most talked-about applications, including embolization for knee osteoarthritis pain, remain promising but far from settled.
The review, led by Jean-Pierre Pelage and colleagues, was designed as a narrative synthesis rather than a systematic review or meta-analysis. The authors searched PubMed/MEDLINE, Embase, Scopus, and Google Scholar, with the final search completed on June 24, 2026. They explicitly avoided formal PRISMA-based selection, risk-of-bias assessment, and quantitative pooling, and they declined to report an included-study count because identification was not a systematic screening process. That transparency matters, because the field they describe spans procedures with radically different levels of proof.
The authors divide musculoskeletal embolization into six broad applications: emergency and postoperative hemostasis; tumor-related embolization; adjunctive embolization before or during percutaneous treatment; vascular malformations and aneurysmal bone cysts; recurrent hemarthrosis; and stand-alone pain-directed embolization for osteoarthritis and tendinopathies. Their central argument is that existing reviews often lump these together despite major differences in therapeutic intent, evidence quality, follow-up duration, and clinical maturity. Treating them as one homogeneous field, they contend, obscures both what is proven and what is still hypothesis.
The strongest evidence belongs to hemostasis. In pelvic ring injuries from high-energy trauma, exsanguination from intrapelvic bleeding is a leading cause of early death. Arterial bleeding is identified in roughly 5 to 20 percent of cases, more often in hemodynamically unstable patients, and embolization achieves technical success rates of 81 to 100 percent. Management now hinges on contrast-enhanced whole-body CT in stable or transiently responding patients to find active extravasation or target vessels, while unstable patients go rapidly to angiography. Contrast extravasation appears in 61 to 100 percent of angiographic cases but can be absent because of spasm, low pressure, or intermittent bleeding. Recurrent bleeding rates range from 0 to 19 percent, with risk factors including initial nonselective embolization, massive transfusion needs, and multivessel involvement.
Technique matters enormously. Resorbable gelatin sponge is the workhorse agent, with large particles above 700 micrometers suited to proximal occlusion. Combined strategies perform distal particulate embolization first, then proximal coils to protect normal vasculature. Pseudoaneurysms call for a sandwich technique with coils placed both distal and proximal to the lesion, and liquid embolics such as n-butyl cyanoacrylate can be used in selected cases with low reported rebleeding rates. Complications like skin necrosis or nerve injury are uncommon when selective techniques are used. The same logic extends to postoperative hemorrhage after major orthopedic surgery, where embolization has been shown to be safe and effective after hip procedures, and to tumor care, where pre-operative devascularization of hypervascular bone tumors, used since 1974, reduces estimated intraoperative blood loss. Reported rates include 93 percent technical success and post-procedural angiograms showing more than 80 percent tumor devascularization in 72 to 100 percent of cases.
Tumor-related embolization, the review stresses, must be interpreted by intent. Pre-operative devascularization, palliation of intractable pain, treatment of selected benign lesions, and adjunctive use before ablation or cementoplasty are distinct goals with distinct evidence. One retrospective series of 164 patients with spinal metastases reported at least a 50 percent reduction in pain scores and analgesic requirements in 97 percent of patients, with a mean pain-relief duration of 9.2 months, but the authors caution that single-cohort retrospective data should not be generalized to all musculoskeletal tumors. Combination strategies are also emerging: in a comparison of 100 patients with pelvic bone metastases, adding transarterial chemoembolization to osteoplasty produced similar pain and functional outcomes to osteoplasty alone but a higher early tumor response rate at one month, 74 percent versus 52 percent.
Then comes the field’s most contested frontier: stand-alone pain-directed embolization. Here the rationale is that chronic degenerative and inflammatory conditions are driven partly by pathological neovascularization, fragile new vessels that sustain inflammatory signaling and serve as conduits for nociceptive nerve ingrowth. By selectively embolizing these abnormal neovessels, the procedure aims to reduce hypervascularity, damp inflammatory mediator delivery, and promote regression of perivascular nerves. Genicular artery embolization for knee osteoarthritis is the flagship application, and the review treats it with unusual candor. Prospective cohorts and single-arm trials report high technical success and pain and function improvements sometimes lasting 12 to 24 months, and the LipioJoint-1 trial, a prospective multicenter single-arm study, reported meaningful relief with a favorable safety profile for Lipiodol-based embolization.
But the sham-controlled evidence tells a different story. One randomized comparison found no significant benefit over sham at four months, and in the subsequent 12-month report both groups had sustained pain improvement with no significant between-group differences in pain, synovitis, or other clinical outcomes, leading those investigators to conclude the findings did not support routine clinical implementation. Against that, the 2026 Society of Interventional Radiology position statement supports genicular artery embolization as a viable joint-preserving option for appropriately selected patients who have failed conservative treatment and are not candidates for, or wish to delay, arthroplasty, while calling for larger randomized trials. The review’s synthesis is a cautious, individualized interpretation rather than routine use. Notably, a prospective single-arm study reported significant reductions in circulating vascular endothelial growth factor and interleukin-1 receptor antagonist at 12 months, and MRI features such as synovitis and bone marrow lesions were associated with better response, suggesting the procedure may work best in knees with active inflammatory features rather than end-stage degeneration.
Beyond the knee, the picture grows more exploratory. For lateral epicondylitis, a prospective 24-patient pilot study reported mean maximum-pain visual analog scores falling from 77 millimeters at baseline to 16 at six months, 9 at 12 months, and 11 at 24 months, with postprocedural MRI showing tendinosis improvement without muscle loss or cartilage or bone necrosis. Encouraging, yes, but from a small uncontrolled cohort. A separate study of ten patients with refractory medial epicondylitis reported significant pain reduction without major adverse events. Plantar fasciitis and Achilles tendinopathy have been investigated on the same neovascularity rationale, but the evidence is limited and heterogeneous, and spontaneous improvement within months makes causal interpretation particularly difficult. The largest plantar fasciitis cohort described 66 cases with up to four years of follow-up, yet most procedures were ultrasound-guided and patients underwent a mean of 2.3 reinterventions. Adhesive capsulitis embolization remains exploratory too, with a recent multicenter study finding ethiodized oil-based embolization feasible and safe for shoulder pain, but small samples and the disease’s natural history prevent firm conclusions about treatment effect.
The review also documents a quieter success story: recurrent hemarthrosis. In non-hemophilic recurrent bleeding after joint replacement, a recent review found technical success in 99 percent of patients, a post-embolization recurrent bleeding rate of 10 percent with a mean time to recurrence of 8.1 months, major complications in 2 percent of cases, and minor complications in 6 percent. All transient skin complications occurred after use of spherical particles smaller than 300 micrometers or n-butyl cyanoacrylate, prompting a recommendation for particles above 300 micrometers and avoidance of proximal coils, which can compromise later arterial access. In patients with hemophilia, embolization significantly reduced bleeding episodes over the following year. The overall message is one of disciplined optimism: hemostatic and selected tumor-related uses are established components of multidisciplinary care, while pain-directed procedures demand careful patient selection, standardized outcome assessment, and comparative trials to define durability and clinical value. The technique is expanding; the proof, indication by indication, is still being earned.
Subject of Research: Indication-stratified narrative review of transarterial embolization across musculoskeletal conditions
Article Title: Transarterial embolization in musculoskeletal care: an indication-stratified narrative review
Article References: Pelage, J.-P., Aldalmani, T., Geevarghese, R., Zhang, N., Jegonday, M.-A., Berry, G., Dohan, A., Fohlen, A., & Grange, S. (2026). Transarterial embolization in musculoskeletal care: an indication-stratified narrative review. CVIR Endovascular, 9(1), Article 127. https://doi.org/10.1186/s42155-026-00776-7
Image Credits: AI Generated
DOI: 10.1186/s42155-026-00776-7
Keywords: transarterial embolization, interventional radiology, genicular artery embolization, knee osteoarthritis, bone tumors, pelvic trauma, tendinopathy, adhesive capsulitis, hemarthrosis, embolic agents, pain management, Transarterial
News Source: Ophelia Keating. (October 29, 2026). From Stopping Bleeds to Easing Knee Pain: How Embolization Is Reshaping Musculoskeletal Care. Scienmag.
